Aktienanalyse zu iRhythm Holdings, Inc (IRTC)IRTCiRhythm Holdings, Inc

iRhythm Holdings, Inc. is a digital health care company that creates solutions that detect, predict, and prevent disease. Combining its Zio wearable biosensors and cloud-based data analytics with proprietary algorithms, the Company distills data from millions of heartbeats into clinically actionable information. Each iRhythm ACM System combines a wire-free, patch-based, 14-day wearable biosensor (FDA-cleared, CE-marked and/or Japan PMDA-approved, as applicable) that continuously records ECG data with a proprietary, cloud-based data analytic software (FDA-cleared, CE-marked, and Japan PMDA-approved) to help physicians monitor patients and diagnose arrhythmias. The Company's products include the Zio monitor (long-term continuous monitoring) and Zio AT (mobile cardiac telemetry (MCT) monitoring). Its VitalConnect platform offers differentiated features such as up to 30-day patient monitoring, four-in-one functionality, flexible service models and live look-in. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

iRhythm Technologies Inc (IRTC) is currently priced at $106.70, which is significantly below the analyst price targets of $150 and $196. However, the stock has a low RSI of 42.12, indicating it may not be oversold yet. The company's recent Q2 results showed a revenue of $224.17 million and a narrowed net loss, which is promising, but the stock has seen a year-to-date decline of 39.11%. The main risk is the high forward P/E ratio of 90.91, suggesting that the stock may be overvalued based on future earnings expectations. Therefore, while there are positive catalysts such as revenue guidance increase and acquisition plans, the current market sentiment and performance trends suggest holding rather than buying at this time.

4 analysts cover IRTC: 3 rate it Buy, 1 Hold and 0 Sell. The average price target is 222.00.